Related Experiment Video

Updated: Jul 8, 2025

Identification Of Erythromyeloid Progenitors And Their Progeny In The Mouse Embryo By Flow Cytometry
08:59

Identification Of Erythromyeloid Progenitors And Their Progeny In The Mouse Embryo By Flow Cytometry

Published on: July 17, 2017

13.0K

Therapeutic targeting of the functionally elusive TAM receptor family

Yu Rebecca Miao1, Erinn B Rankin1, Amato J Giaccia2

  • 1Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA.

Nature Reviews. Drug Discovery
|December 13, 2023
PubMed

Insights

TAM receptor inhibitors targeting TYRO3, AXL, and MERTK show promise for cancer and other diseases. This review explores their therapeutic potential and current clinical challenges.

Area of Science:

  • Molecular biology
  • Immunology
  • Oncology

Background:

  • The TAM receptor tyrosine kinase family (TYRO3, AXL, MERTK) is crucial for tissue and immune homeostasis.
  • Dysregulated TAM signaling is implicated in diseases like cancer, fibrosis, and viral infections, promoting tumor growth and metastasis.
  • TAM receptors influence key oncogenic pathways including epithelial-mesenchymal transition, stemness, immune evasion, proliferation, angiogenesis, and therapy resistance.

Purpose of the Study:

  • To provide biological and clinical insights into TAM receptor inhibitors.
  • To evaluate the therapeutic potential of TAM receptor inhibitors for cancer and non-malignant diseases.

Main Methods:

  • Review of preclinical and clinical data on TAM receptor inhibitors.
  • Analysis of the role of TAM receptors in various disease pathologies.
  • Evaluation of the clinical development status of TAM receptor inhibitors, particularly AXL inhibitors.

Main Results:

  • Multiple TAM receptor inhibitors are in development, with AXL inhibitors being the most advanced clinically.
  • TAM receptor dysregulation contributes to tumor progression and resistance to therapies.
  • Inhibitors targeting TAM receptors offer potential therapeutic strategies for various cancers and non-malignant conditions.

Conclusions:

  • TAM receptor inhibitors represent a promising therapeutic avenue for cancer and non-malignant diseases.
  • Despite clinical advancements, challenges in the development and application of these inhibitors remain.
  • Further research is needed to fully elucidate the therapeutic potential and optimize the use of TAM receptor inhibitors.

More Related Videos

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

18.7K
Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

2.5K

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
78.5K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
13.0K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.3K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
174